Hepatitis B reactivation and rituximab: A new boxed warning and considerations for solid organ transplantation

American Journal of Transplantation

Volumn 14, Issue 4, 2014, Pages 788-796

  Martin, S T ^a   Cardwell, S M ^a   Nailor, M D ^a,b   Gabardi, S ^c,d  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hepatitis B virus; immunosuppression; rituximab; solid organ transplantation

Indexed keywords

CD20 ANTIGEN; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; OFATUMUMAB; RITUXIMAB; TELBIVUDINE; TENOFOVIR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIVIRAL THERAPY; ARTICLE; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OFF LABEL DRUG USE; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; SEROCONVERSION; SEROLOGY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REACTIVATION; VIRUS REPLICATION; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SURVEILLANCE PROGRAM; PRACTICE GUIDELINE; PROGNOSIS; RISK FACTOR; UNITED STATES; VIROLOGY; VIRUS ACTIVATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRUS ACTIVATION;

EID: 84897110116     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12649     Document Type: Article

References (40)

1. Lok AS, McMahon BJ., Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661-662.
2. Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 1988; 94: 151-156.
3. Rituxan (rituximab) package insert. South San Francisco, CA: Genentech, Inc., 2013, September.
4. Suzan F, Ammor M, Ribrag V., Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
5. Sharma VR, Fleming DR, Slone SP., Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96: 1184-1186.
6. Bermúdez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A., Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85: 894-895.
7. Arzerra (ofatumumab) and Rituxan (rituximab): Drug safety warning-New boxed warning, recommendations to decrease risk of hepatitis B reactivation. US Food and Drug Administration 2013. Available at: http://www.fda.gov/safety/ medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm369846.htm. Accessed November 20, 2013.
8. Lok AS, McMahon BJ., Chronic hepatitis B. Hepatology 2007; 45: 507-539.
9. Pescovitz MD., Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6: 859-866.
10. Ganem D, Prince AM., Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
11. Mason A, Theal J, Bain V, Adams E, Perillo R., Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease. Am J Gastroenterol 2005; 100: 972-976.
12. Sprengers D, van der Molen RG, Kusters JG, et al. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. J Hepatol 2006; 45: 182-189.
13. Kliem V, Burg M, Haller H, et al. Relationship of hepatitis B or C virus prevalence, risk factors, and outcomes in renal transplant recipients: Analysis of German data. Transplant Proc 2008; 40: 909-914.
14. Fishman J, Rubin RH., Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
15. Coffin CS, Terrault NA., Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007; 14 (Suppl 1): 37-44.
16. Dervite I, Hober D, Morel P., Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
17. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y., Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis. J Clin Virol 2013; 57: 209-214.
18. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M., Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116: 4769-4776.
19. Tsutsumi Y, Shigematsu A, Hashino S, et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol 2009; 88: 375-377.
20. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
21. Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013; 49: 3486-3496.
22. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative disease: Meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-1180.
23. Lazdina U, Alheim M, Nyström J, et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 2003; 84: 139-146.
24. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-2930.
25. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
26. Nainan OV, Kristova ML, Byan K, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002; 68: 319-327.
27. Weinbaum CM, Williams I, Mast EE, et al. Recommendation for the identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
28. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant disease. J Clin Oncol 2010; 28: 3199-3202.
29. Chew E, Thursky K, Seymour JF., Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: The need for continued vigilance. Leuk Lymphoma 2013; doi: 10.3109/10428194.2013.813502 [Epub ahead of print].
30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
31. He YF, Li YH, Wang FH, et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481-485.
32. Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ., The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012; 29: 1237-1241.
33. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772.
34. Kim JS, Hahn JS, Park SY, et al. Long term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in Non-Hodgkin's Lymphoma. Yonsei Med J 2007; 48: 78-79.
35. Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011; 18: 877-883.
36. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306.
37. Köklü S, Tuna Y, Gülşen MT, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013; 11: 88-94.
38. Blanpain C, Knoop C, Delforge ML, et al. Reactivation of hepatitis B after transplantation in patient with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature. Transplantation 1998; 66: 883-886.
39. Fylaktou A, Daoudaki M, Dimou V, et al. Hepatitis B reactivation in a renal transplant patient due to a surface antigen mutant strain: A case report. Transplant Proc 2012; 44: 2773-2775.
40. Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA., Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: A note of caution. Clin Transplant 2009; 23: 431-434.